Testing cryopreserved European eel sperm for hybridization (A. japonica × A. anguilla)

[EN] The objective of this study was to assess impact of cryopreserved European eel sperm and Japanese eel native sperm on early fertilization, hatch, survival, and malformation rates of larvae, as well as develop molecular techniques to distinguish different eel species. Eggs from Japanese eel females (Anguilla japonica) were artificially fertilized with sperm of Japanese eel males and cryopreserved sperm from European eel (A. anguilla, extender was modified Tanaka solution and methanol as cryoprotectant). There were no statistical differences (p¿>¿0.05) among the measured parameters such as fertilization, hatch and survival after 10 days post-hatch rates due to large individual differences. The malformation rate of larvae compared to the hatching rate was higher in cryopreserved groups than in the control indicating that the methodology needs further refinement. Genetic analyses (PCR-RFLP, PCR-HRM) proved a clear result in the detection of paternal contribution in hybridization between the Japanese and the European eel and applied PCR-HRM method is a quick and cost effective tool to identify illegally imported A. anguilla at the glass eel stage, which can be transported from Europe to Asia.The research was supported by The Ministry of Education, Culture, Sports, Science and Technology (MEXT)/Japan Society for the Promotion of Science (JSPS) Kakenhi Grant No.15K07562 and Tokyo University of Agriculture Strategic Research Program (TUA-SRP), Mohamed bin Zayed Species Conservation Fund (grant number 12252178), GINOP-2.3.2-15-2016-00054 project of the National Research, Development and Innovation Office of Hungary and EFOP-3.6.3-VEKOP-16-2017-00008 project. The project is co-financed by the European Union, the European Social Fund and KMR_12-1-2012-0435.Müller, T.; Matsubara, H.; Kubara, Y.; Horváth, Á.; Kolics, B.; Taller, J.; Stéger, V.... (2018). Testing cryopreserved European eel sperm for hybridization (A. japonica × A. anguilla). Theriogenology. 113:153-158. https://doi.org/10.1016/j.theriogenology.2018.02.021S15315811

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)

Population genetics on <em>Ambrosia</em> genus: past, present and future

National audienceA new Task Force within the COST-SMARTER has recently been created. This group is composed of population genetics experts from five European countries in charge of focusing on “Genetics on Ambrosia” (Austria, France, Germany, Hungary, Sweden). Their mission was to review molecular methods used in published genetics studies on common ragweed and to discuss about future projects. Two different types of molecular markers are generally used in the literature to investigate the genetic structure within and between introduced and/or native populations of common ragweed: microsatellite markers and amplified fragment length polymorphism (AFLP). These methods permit the researchers to trace-back the common ragweed invasion history and its worldwide spread as well as to identify certain evolutionary processes like selection, adaptation or genetic bottleneck due to introduction. One common conclusion is the presence of two main genetic clusters within Europe coming from two different regions of the native range. However, this conclusion is based on a limited number of microsatellite markers used (12 nuclear + 4 plastid). New methods using haplotype analysis or selected markers present on functional parts of the genome (i.e., related to herbicide-resistance) should be more investigated in order to increase the knowledge on common ragweed. Transcriptomic analyses are starting to be employed in USA to observe gene expression related to adaptations and identify the genes of the “invasiveness”. These new methods will now be promoted within the different European projects in order to open the way of whole-genome sequencing of Ambrosia artemisiifolia in the future